Mitochondrial disease drug napazimone: pivotal FALCON trial now expects full enrollment in the first half of 2027

Edited by Samael A. Tejada, Founder & Editor-in-Chief

For readers who follow mitochondrial medicine, the useful discipline is separating a drug that exists from a drug that works. Napazimone exists, it is in a properly pivotal trial in adults with mtDNA-driven disease, and this update says that trial is filling — more slowly than a finished trial, faster than a stalled one. Everything about benefit is still ahead of the data.

What exactly did the October 27 update say?

In its third-quarter 2026 results (Leiden, October 27, 2026), Pharming Group described napazimone (KL1333) as 'being evaluated in the pivotal FALCON clinical trial in adult patients with mtDNA-driven mitochondrial disease' with 'the potential to become the first standard of care in this setting.' The operational facts: over 50 clinical sites are actively recruiting, with significant expansion achieved in the US; approximately 145 of the planned 180 subjects are expected to be enrolled by the end of 2026; enrollment is now expected to complete in the first half of 2027; and topline results are expected approximately one year after enrollment completes — which places them in 2028 on the company's own arithmetic.

Why does a recruitment update matter in mitochondrial disease?

Primary mitochondrial diseases are rare, genetically varied and hard to trial: recruiting 180 adults with mtDNA-driven disease across more than 50 sites is itself a measure of feasibility that earlier mitochondrial programs have struggled to reach. A pivotal design means the trial is intended to be capable of supporting a regulatory decision if it succeeds — which is why the enrollment pace, not any interim claim, is the news here. The same quarterly report was dominated by Pharming's marketed products (RUCONEST and Joenja); napazimone is a pipeline program the company acquired with Abliva, and its progress is reported in operational milestones until efficacy data exist.

What should readers not take from this update?

Three things. First, no efficacy: the update contains no FALCON outcome data, no interim analysis and no patient-reported results. Second, no availability: napazimone is investigational, is not approved anywhere, and outside the trial there is no established access route. Third, no certainty about the timeline itself: enrollment forecasts in rare-disease trials slip routinely, and 'expected approximately one year after enrollment completes' is a company projection. The honest next milestone to watch is the one the company named — completed enrollment in the first half of 2027.

Where the evidence stands

• Established: mtDNA-driven primary mitochondrial disease has no approved standard-of-care therapy; napazimone (KL1333) is an investigational candidate being evaluated in the pivotal FALCON trial in adults.
• Preliminary: Per Pharming Group's Q3 2026 report (Oct 27, 2026): over 50 FALCON sites actively recruiting with US expansion, about 145 of 180 planned participants expected enrolled by end of 2026, enrollment completion expected in H1 2027, and topline results expected about one year after enrollment completes.
• Absent: Any FALCON efficacy or safety results, any regulatory filing or approval, and any access to napazimone outside the clinical trial.